Results 181 to 190 of about 24,047,971 (353)

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Cancer Research Funding in Africa. [PDF]

Commun Med (Lond)
Afolaranmi O, Garton EM, Dada OE, Virani SS, Shour AR, Onitilo AA, Zafar SN.   +6 more
europepmc   +1 more source

Advances in Cancer Research. Vol 7. [PDF]

, 1963
Gunnar Klein, Sidney Weinhouse
openalex   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Cancer research and the mainstream of biology. [PDF]

Front Cell Dev Biol
Maimets T.
europepmc   +1 more source

An introduction to cancer research

, 1950
G. Burroughs Mider
openalex   +1 more source

Sixteenth Annual Symposium on Fundamental Cancer Research [PDF]

, 1961

openalex   +1 more source

Progress of Cancer Research [PDF]

Nature, 1947
openaire   +5 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Applying physical principles to cancer research. [PDF]

APL Bioeng
Fischbach C, O'Hern CS, Engler AJ.
europepmc   +1 more source